Pınar Fatma Yıldız

Pınar Fatma Yıldız

Auto-generated profile, based on publicly available information

Pınar Fatma Yıldız

Department of Obstetrics and Gynecology, Bolu Abant İzzet Baysal University Training and Research Hospital , Bolu 14030

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

2 September 2026 in Sexual Medicine
Verified
Journal Article
Open access
FDFunda Dağıstanlı
Funda Dağıstanlı
PYPınar Fatma Yıldız
Pınar Fatma Yıldız
IŞİhSan Şafak
İhSan Şafak
MEMustafa Ayhan Ekici
Mustafa Ayhan Ekici
Introduction: Bartholin gland disease impairs sexual function, yet most studies focus on surgical technique rather than the broader sexual health burden, and none has systematically examined sexual distress or genital self-image in this population. We aimed to characterize the sexual health burden of Bartholin gland disease across four domains: pain (Visual Analogue Scale [VAS]), sexual function (Female Sexual Function Index [FSFI]), sexual distress (Female Sexual Distress Scale-Revised [FSDS-R]), and genital self-image (Female Genital Self-Image Scale [FGSIS]), at two time points (before and after treatment) and to compare findings against matched healthy controls. Methods: This prospective cohort study enrolled 25 women diagnosed with a Bartholin gland cyst or abscess (patient group) and 25 age-matched healthy controls at a single training and research hospital. Patients were evaluated twice: at presentation before any treatment (T1) and after symptom resolution (T2). Controls were assessed once. Outcome measures were the VAS (applied to patients only), FSFI (cut-off <26.55), FSDS-R (cut-off ≥11), and FGSIS. Sample size was calculated a priori (d = 0.80, α = 0.05, power = 80%; G*Power 3.1). Results and Discussion: Groups were comparable for age (36.1 ± 6.6 vs. 34.2 ± 7.6 years, P = .472), body mass index (BMI), and parity. At T1, 48.0% of patients had clinically significant sexual dysfunction (FSFI <26.55) and 16.0% met the distress threshold (FSDS-R ≥ 11). All four scales improved significantly from T1 to T2 (P < .001 for each). By T2, FSFI (31.72 ± 3.34 vs. 31.11 ± 1.87, P = .187), FSDS-R (1.44 ± 1.69 vs. 0.56 ± 0.65, P = .068), and FGSIS (24.40 ± 2.33 vs. 23.20 ± 1.94, P = .066) no longer differed from controls. Notably, FGSIS was already similar between patients and controls at T1 (22.92 ± 3.28 vs. 23.20 ± 1.94, P = .784). VAS pain scores fell from 5.96 ± 2.64 to 1.04 ± 0.20 (effect size dz = 1.906). T1 FSFI scores did not differ by pathology type (cyst vs. abscess, P = .479) or surgical procedure (P = .866). Strong correlations were observed between FSFI and FSDS-R (r = −0.829, P < .001) and between VAS and FSDS-R (r = +0.561, P = .004). Bartholin gland disease carries a measurable sexual health burden that substantially resolves after treatment. Genital self-image appears to remain intact even during active disease. Systematic screening with FSFI and FSDS-R should be integrated into routine management; surgical decision-making should account for the higher dyspareunia risk associated with marsupialization.

1 June 2026
Verified
Book
Open access
PDF file
YDYıldırım Durak
Yıldırım Durak
AKAybike Kınık Karabaş
Aybike Kınık Karabaş
FGFatmanur Ceylan Genç
Fatmanur Ceylan Genç
PYPınar Fatma Yıldız
Pınar Fatma Yıldız
EAElif Aydın
Elif Aydın
FDFunda Dağıstanlı
Funda Dağıstanlı